```
=> fil hcaplu
FILE 'HCAPLUS' ENTERED AT 15:39:10 ON 03 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Feb 2003  VOL 138 ISS 6
FILE LAST UPDATED: 2 Feb 2003  (20030202/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 15:07:22 ON 03 FEB 2003)

     FILE 'REGISTRY' ENTERED AT 15:07:34 ON 03 FEB 2003
                E MS-HBP1/CN
                E MS-HBP1
                E MSHBP1/CN
                E MSHBP1
L1              2 S MS(W)(HBP1 OR HBP(W)1)
                E FS-HBP1/CN
L2              2 S FS(W)(HBP1 OR HBP(W)1)
                E FS-HBP2/CN
                E FS-HBP2
L3              2 S FS(W)(HBP2 OR HBP(W)2)
                E D-RET 6/CN
                E D.RET 6/CN
                E D-RET 6/CN
L4              1 S E4
L5              2 S D(W)(RET6 OR RET(W)6)
                E HISTALCALIN/CN
                E HISTACALIN/CN
L6              1 S E2
                E HISTACALIN PROTEIN/CN

     FILE 'HCAPLUS' ENTERED AT 15:30:21 ON 03 FEB 2003
L7              5 S L1 OF MS(W)(HBP1 OR HBP(W)1)
L8              5 S L2 OF FS(W)(HBP1 OR HBP(W)1)
L9              5 S L3 OF  FS(W)(HBP2 OR HBP(W)2)
L10           289 S L4 OR L5 OR D(W)(RET6 OR RET(W)6)
L11           315 S L6 OR HISTACALIN?
L12             6 S L7 OR I8 OR L9 OR L10 AND (?CONJUNCT OR EYE? OR OCUL?)

     FILE 'HCAPLUS' ENTERED AT 15:39:10 ON 03 FEB 2003
```

=> d ibib abs hitrn l12 1-6

L12 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:168020 HCAPLUS
DOCUMENT NUMBER: 134:217189
TITLE: Treatment of allergic rhinitis with proteins from ticks
INVENTOR(S): Nuttall, Patricia Anne; Paesen, Guido Christiaan
PATENT ASSIGNEE(S): Evolutec Limited, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016164	A2	20010308	WO 2000-GB3287	20000824
WO 2001016164	A3	20010503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013655	A	20020507	BR 2000-13655	20000824
EP 1207899	A2	20020529	EP 2000-954788	20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2002193306	A1	20021219	US 2002-87195	20020301

PRIORITY APPLN. INFO.: GB 1999-20673 A 19990901
WO 2000-GB3287 W 20000824

AB The invention relates to the discovery that various proteins isolated from ticks are effective in the treatment and prevention of allergic rhinitis. These proteins may most suitably be applied to an effected area and are thus effective to treat this condition and to ameliorate its symptoms. Human subjects were challenged with histamine and then were treated with histamine-binding protein, **MS-HBP1**.

L12 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:167826 HCAPLUS
DOCUMENT NUMBER: 134:217188
TITLE: use of histacalin protein for treatment or prevention of conjunctivitis
INVENTOR(S): Nuttall, Patricia Anne; Paesen, Guido Christiaan
PATENT ASSIGNEE(S): Evolutec Limited, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001015719 A2 20010308 WO 2000-GB3282 20000824
WO 2001015719 A3 20010510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
BR 2000013665 A 20020514 BR 2000-13665 20000824
EP 1207898 A2 20020529 EP 2000-954784 20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
US 2002151499 A1 20021017 US 2002-85572 20020227
PRIORITY APPLN. INFO.: GB 1999-20674 A 19990901
WO 2000-GB3282 W 20000824

AB Various histacalin proteins isolated from ticks are effective in the treatment of conjunctivitis. These proteins may most suitably be applied topically to an affected area and are effective to ameliorate the symptoms of this condition.

L12 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:374997 HCAPLUS
DOCUMENT NUMBER: 131:154999
TITLE: Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure
AUTHOR(S): Paesen, G. C.; Adams, P. L.; Harlos, K.; Nuttall, P. A.; Stuart, D. I.
CORPORATE SOURCE: Institute of Virology and Environmental Microbiology, Natural Environment Research Council, Oxford, OX1 3SR, UK
SOURCE: Molecular Cell (1999), 3(5), 661-671
CODEN: MOCEFL; ISSN: 1097-2765
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB High-affinity histamine-binding proteins (HBPs) were discovered in the saliva of Rhipicephalus appendiculatus ticks. Their ability to outcompete histamine receptors indicates that they suppress inflammation during blood feeding. The crystal structure of a histamine-bound HBP, detd. at 1.25 .ANG. resoln., reveals a lipocalin fold novel in contg. two binding sites for the same ligand. The sites are orthogonally arranged and highly rigid and form an internal surface of unusual polar character that complements the physicochem. properties of histamine. As sol. receptors of histamine, HBPs offer a new strategy for controlling histamine-based diseases.

IT **200220-32-2 200220-33-3 200220-34-4**
RL: PRP (Properties)
(amino acid sequence; isolation, cloning, mol. characterization and three-dimensional structure of sex-specific tick histamine-binding proteins)

IT **200220-28-6**, GenBank U96080 **200220-29-7**, GenBank U96081
200220-30-0, GenBank U96082
RL: PRP (Properties)
(nucleotide sequence; isolation, cloning, mol. characterization and three-dimensional structure of sex-specific tick histamine-binding proteins)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:359659 HCAPLUS
DOCUMENT NUMBER: 131:28315
TITLE: Cloning and functions of vasoactive amine-binding proteins from ticks
INVENTOR(S): Nuttall, Patricia Ann; Paesen, Guido Christian
PATENT ASSIGNEE(S): Oxford Vaccine Ltd., UK
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9927104	A1	19990603	WO 1998-GB3530	19981126
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309809	AA	19990603	CA 1998-2309809	19981126
AU 9911511	A1	19990615	AU 1999-15511	19981126
EP 1034273	A1	20000913	EP 1998-955786	19981126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
BR 9815056	A	20001003	BR 1998-15056	19981126
JP 2002500927	T2	20020116	JP 2000-522246	19981126

PRIORITY APPLN. INFO.: GB 1997-25046 A 19971126
GB 1998-13917 A 19980626
WO 1998-GB3530 W 19981126

AB The present invention relates to histamine and serotonin binding mols. that possess a binding site with the precise mol. configuration that is necessary to confer on the mol. a high affinity for histamine. The invention includes proteins, peptides and chem. compds. that possess this mol. configuration and that are thus able to bind to histamine with high affinity. These mols. may be used in the regulation of the action of histamine or serotonin, the detection and quantification or histamine or serotonin and in the treatment of various diseases and allergies. The mols. may also be used as components of vaccines directed against blood-sucking ectoparasites. Vasoactive amine binding proteins (VABPs) are provided that specifically bind to vasoactive amines with a dissocn. const. of <10-7 M and which belong to the same protein family as **MS-HBP1**, **FS-HBP1**, **FS-HBP2** and D.RET6. Thus, 11 VABPs were isolated, and their cDNAs cloned and sequenced, from ticks: **FS-HBP1** (female-specific histamine-binding protein 1), **FS-HBP2** (female-specific histamine-binding protein 2), **MS-HBP1** (male-specific histamine-binding protein 1), and Ra-Res from Rhipicephalus appendiculatus; D.RET6 from Dermacenter reticularis; Av-HBP from Amblyomma variegatum; and 5 related Ih/Bm-HBP proteins from a mixed Ixodes hexagonus/Boophilus microplus cDNA expression library. These VABPs possess similar amino acid sequences and predicted secondary structures.

The VASPs bind histamine in mammals, and can be used as anti-inflammatory agents to regulate histamine action and to control its pathol. effects. The crystal structure of **FS-HBP2** to 2.24 .ANG. resoln. was used to design a synthetic cyclic octapeptide (-Ala-Glu-Ala-Phe-Ala-Glu-Ala-Trp-) with histamine binding activity.

IT **200220-32-2 200220-33-3 200220-34-4**
PL: BAC (Biological activity or effector, except adverse); BPP (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(amino acid sequence; cloning and functions of vasoactive amine-binding proteins from ticks)

IT **200220-28-6P 200220-29-7P 200220-30-0P**
PL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; cloning and functions of vasoactive amine-binding proteins from ticks)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:270816 HCAPLUS
DOCUMENT NUMBER: 131:53579
TITLE: Inhibitory effects of tetrandrine and related synthetic compounds on angiogenesis in streptozotocin-diabetic rodents
AUTHOR(S): Kobayashi, Shinjiro; Kimura, Ikuko; Fukuta, Mizuki; Kontani, Hitoshi; Inaba, Kazuhiko; Niwa, Masashi; Mita, Shiro; Kimura, Masayasu
CORPORATE SOURCE: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, 920-1181, Japan
SOURCE: Biological & Pharmaceutical Bulletin (1999), 22(4), 360-365
CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Structure-activity relationships of tetrandrine, isolated from a Kampo medicine, Stephania tetrandrae S. Moore (root), and related synthetic compds., were investigated in in vitro fetal bovine serum (FBS)-stimulated angiogenesis of cultured choroids in streptozotocin-diabetic Wistar rats, and air-pouch granuloma angiogenesis in vivo in diabetic mice. Tetrandrine, KS-1-1 (6,7-dimethoxy-1-[[4-[5-(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinyl)methyl-2-methoxy]phenoxy]benzyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline), and KS-1-4 (6,7-dimethoxy-1-[[4-[4-(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinyl)methyl]phenoxy]benzyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline), potently inhibited choroidal angiogenesis and air-pouch granuloma angiogenesis in the diabetic state. Their inhibitory effects on diabetic choroids were greater than those on normal choroids. Among these compds., KS-1-4 inhibited only diabetic angiogenesis. These compds. significantly inhibited FBS-stimulated tube formation in vascular endothelial cells from normal rats. Tetradrine and KS-1-4, but not KS-1-1, inhibited vascular endothelial growth factor- and platelet-derived growth factor-BB-stimulated angiogenesis in normal choroids. The bis[tetrahydroisoquinoline] moiety, connected by oxy-bis[phenylenemethylene] and 2,2'-dimethyl groups in tetrandrine, contributes to the inhibition of diabetic choroidal angiogenesis. KS-1-4 may be a candidate for anti-choroidopathy and retinopathy drugs in the diabetic state.

Searched by M. Smith

IT **485-19-8**, (+)-Reticuline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibitory effects of tetrandrine and related synthetic compds. on angiogenesis in streptozotocin-diabetic rodents)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:776255 HCAPLUS
DOCUMENT NUMBER: 128:57765
TITLE: Cloning and functions of vasoactive amine-binding proteins from ticks
INVENTOR(S): Paesen, Guido Christian; Nuttall, Patricia Ann
PATENT ASSIGNEE(S): Oxford Vacs Ltd., UK; Paesen, Guido Christian; Nuttall, Patricia Ann
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9744452	A2	19971127	WO 1997-GB1372	19970519
WO 9744452	A3	19980219		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253924	AA	19971127	CA 1997-2253924	19970519
AU 9729071	A1	19971209	AU 1997-29071	19970519
AU 725630	B2	20001019		
EP 906425	A2	19990407	EP 1997-923104	19970519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
BR 9709101	A	19990803	BR 1997-9101	19970519
CN 1225683	A	19990811	CN 1997-196317	19970519
JP 2000512489	T2	20000926	JP 1997-541799	19970519

PRIORITY APPLN. INFO.: GB 1996-10484 A 19960518
GB 1997-7844 A 19970413
WO 1997-GB1372 W 19970519

AB Vasoactive amine binding proteins (VABPs) are provided that specifically bind to vasoactive amines with a dissocn. const. of <10-7 M and which belong to the same protein family as **MS-HBP1**, **FS-HBP1**, **FS-HBP2** and D.RET6. Thus, 4 VASPs were isolated, and their cDNAs cloned and sequenced, from ticks: **FS-HBP1** (female-specific histamine-binding protein 1), **FS-HBP2** (female-specific histamine-binding protein 2), and **MS-HBP1** (male-specific histamine-binding protein 1) from Rhipicephalus appendiculatus; and D.RET6 from Dermacenter reticularis. These 4 VASPs possess similar amino acid sequences and predicted secondary structures. The VASPs bind histamine in mammals, and can be used as anti-inflammatory agents to regulate histamine action and

to control its pathol. effects.

IT **200220-32-2 200220-33-3 200220-34-4**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PPP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(amino acid sequence; cloning and functions of vasoactive amine-binding proteins from ticks)

IT **200220-28-6P 200220-29-7P 200220-30-0P**
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; cloning and functions of vasoactive amine-binding proteins from ticks)

=> d stat que
L1 2 SEA FILE=REGISTRY MS(W)(HBP1 OR HBP(W)1)
L2 2 SEA FILE=REGISTRY FS(W)(HBP1 OR HBP(W)1)
L3 2 SEA FILE=REGISTRY FS(W)(HBP2 OR HBP(W)2)
L4 1 SEA FILE=REGISTRY D-RETICULINE/CN
L5 2 SEA FILE=REGISTRY D(W)(RET6 OR RET(W)6)
L6 1 SEA FILE=REGISTRY HISTAC/CN
L7 5 SEA FILE=HCAPLUS L1 OR MS(W)(HBP1 OR HBP(W)1)
L8 5 SEA FILE=HCAPLUS L2 OR FS(W)(HBP1 OR HBP(W)1)
L9 5 SEA FILE=HCAPLUS L3 OR FS(W)(HBP2 OR HBP(W)2)
L10 289 SEA FILE=HCAPLUS L4 OR L5 OR D(W)(RET6 OR RET(W)6)
L11 315 SEA FILE=HCAPLUS L6 OR HISTACALIN?
L12 6 SEA FILE=HCAPLUS L7 OR L8 OR L9 OR L10 AND (?CONJUNCT OR EYE? OR OCUL?)
L13 4 SEA FILE=HCAPLUS L11 AND (?CONJUNCT? OR EYE? OR ?OCUL?)
L14 3 SEA FILE=HCAPLUS L13 NOT L12

=> d ibib abs hitrn l14 1-3

L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:795285 HCAPLUS
DOCUMENT NUMBER: 128:110395
TITLE: Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration
AUTHOR(S): Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.
CORPORATE SOURCE: Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SOURCE: American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713
CODEN: AHSPEK; ISSN: 1079-2082
PUBLISHER: American Society of Health-System Pharmacists
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration was studied. Five milliliters of doxorubicin hydrochloride liposome injection 0.4 mg/mL in 5% dextrose injection was combined with 5 mL of each of 82 other drugs in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. The combinations were examd. with the unaided **eye** in fluorescent light and in high-intensity monodirectional light to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as

well. Particle sizing and counting were performed on selected combinations. Evaluations were performed initially and at one and four hours. All combinations were stored at room temp. (.apprx.23 .degree.C). Most of the test drugs were compatible with doxorubicin hydrochloride liposome injection during the four-hour observation period. However, practitioners should be cautious in administering any drug simultaneously with doxorubicin hydrochloride liposome injection until the integrity of the liposomes can be verified. Eighteen drugs exhibited unacceptable increases or decreases in measured turbidity or particulate formation within four hours. During simulated Y-site administration, doxorubicin hydrochloride 0.4 mg/mL (as the liposomal injection) in 5% dextrose injection was compatible with 64 of 82 other drugs for four hours at .apprx.23 .degree.C and was incompatible with 18 of the test drugs.

IT **66357-59-3**, Ranitidine hydrochloride
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study; (doxorubicin hydrochloride liposome injection compatibility with other drugs)

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:678708 HCAPLUS
DOCUMENT NUMBER: 127:325983
TITLE: Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration
AUTHOR(S): Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.; Kim, Mia C.
CORPORATE SOURCE: Division of Pharmacy, Clinical Pharmaceutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SOURCE: American Journal of Health-System Pharmacy (1997), 54(19), 2192-2196
CODEN: AHSPEK; ISSN: 1079-2082
PUBLISHER: American Society of Health-System Pharmacists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The compatibility of remifentanil hydrochloride with 90 other drugs during simulated Y-site administration was studied. Five milliliters of remifentanil 25 and 250 .mu.g/mL (as hydrochloride) in 0.9% sodium chloride injection or 5% dextrose injection was combined with 5 mL of each of 90 other drugs in 5% dextrose injection or 0.9% sodium chloride injection. Each combination was prepd. in duplicate. The combinations were stored at .apprx.23 .degree.C under fluorescent light and examd. with the unaided **eye** and in high-intensity monodirectional light during the first 15 min after prepn. and at one and four hours. The turbidity of each combination was measured as well. Particle sizing and counting were performed for selected combinations. Most of the combinations exhibited no haze, turbidity, or color change throughout the study period. Remifentanil 25 .mu.g/mL combined with chlorpromazine hydrochloride showed a small increase in haze within four hours. One of the combinations of remifentanil 250 .mu.g/mL with cefoperazone sodium was un-acceptably hazy within one hour. The combination of remifentanil 250 .mu.g/mL with amphotericin B formed a gross ppt. upon mixing. Remifentanil 25 and 250 .mu.g/mL (as hydrochloride) in 0.9% sodium chloride injection was compatible for four hours at .apprx.23 .degree.C with all the drugs studied except chlorpromazine hydrochloride (with remifentanil 25 .mu.g/mL), cefoperazone sodium (with remifentanil 250 .mu.g/mL), and amphotericin B (with remifentanil 250 .mu.g/mL in 5% dextrose injection).

IT **66357-59-3**, Ranitidine hydrochloride
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(remifentanil hydrochloride compatibility with 90 pharmaceuticals)

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:321916 HCAPLUS
DOCUMENT NUMBER: 125:18979
TITLE: Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration
AUTHOR(S): Trissel, Lawrence A.; Martinez, Juan F.
CORPORATE SOURCE: M. D. Anderson Cancer Center, University of Texas, Houston, TX, 77030, USA
SOURCE: American Journal of Health-System Pharmacy (1996), 53(9), 1041-1045
CODEN: AHSPEK; ISSN: 1079-2082
PUBLISHER: American Society of Health-System Pharmacists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Five-milliliter samples of thiotepa (lyophilized) (1 mg/mL in 5% dextrose soln.) were combined with 5 mL each of 100 other drugs, including antineoplastics, anti-infectives, and supportive care drugs, in 5% dextrose or 0.9% NaCl. The combinations were stored at room temp. (.apprx.23.degree.) under const. fluorescent light. Visual examns. were performed with the unaided **eye** immediately and after 1 and 4 h and, if there was no obvious incompatibility, with a high-intensity monodirectional light beam to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as well. Particle sizing and counting were performed on selected solns. Two drugs exhibited incompatibilities with thiotepa. The thiotepa-cisplatin combination developed turbidity in 4 h, and the thiotepa-minocycline-HCl combination developed a bright yellow-green discoloration in 1 h. All the other test drugs were compatible with thiotepa for at .gtoreq.4 h at room temp.

IT **66357-59-3**, Ranitidine hydrochloride
RL: MSC (Miscellaneous); PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(physicochem. compatibility of drugs with thiotepa during simulated i.v. administration)

```
Show files
File 155:MEDLINE(R) 1966-2003/Jan W4
         (c)
File   5:Biosis Previews(R) 1969-2003/Jan W4
         (c) 2003 BIOSIS
File  34:SciSearch(R) Cited Ref Sci 1990-2003/Jan W4
         (c) 2003 Inst for Sci Info
File  35:Dissertation Abs Online 1861-2003/Jan
         (c) 2003 ProQuest Info&Learning
File  50:CAB Abstracts 1972-2003/Dec
         (c) 2003 CAB International
File  71:ELSEVIER BIOBASE 1994-2003/Feb W1
         (c) 2003  Elsevier Science B.V.
File  73:EMBASE 1974-2003/Jan W4
         (c) 2003 Elsevier Science B.V.
File  94:JICST-EPlus 1985-2003/Nov W3
         (c)2003 Japan Science and Tech Corp(JST)
File 144:Pascal 1973-2003/Jan W4
         (c) 2003 INIST/CNRS
File 281:ONTAP(R) Gale Group MARS(R)
         (c) 1999 The Gale Group
File 340:CLAIMS(R)/US Patent 1950-03/Jan 30
         (c) 2003 IFI/CLAIMS(R)
File 345:Inpadoc/Fam.& Legal Stat 1968-2002/UD=200304
         (c) 2003 EPO
File 351:Derwent WPI 1963-2003/UD,UM &UP=200307
         (c) 2003  Thomson Derwent
File 357:Derwent Biotech Res. _1982-2003/Feb W1
         (c) 2003 Thomson Derwent & ISI
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
File 440:Current Contents Search(R) 1990-2003/Feb 04
         (c) 2003 Inst for Sci Info
?ds

Set     Items   Description
S1          3   HISTACALIN(5W)PROTEIN? AND (ECTOPARASITE? OR TICK?) AND (C-
               ONJUNCTIVIT? OR EYE? OR OCUL?)
S2          3   RD (unique items)
?t2/7/1-3

 2/7/1      (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2003 IFI/CLAIMS(R). All rts. reserv.

10207792   2002-0151499   2002-0039229
C/TREATMENT OF  CONJUNCTIVITIS
Document Type: Utility
Document Type: Patent Application-First Publication
Inventors: Nuttall Patricia Anne (GB); Paesen Guido Christiaan (GB)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000

                    Publication                 Application
               Kind    Number         Date      Number       Date
               ---- -------------- -------- -------------- --------
                 A1 US 20020151499 20021017 US 200285572   20020227
Continuation of:    UNKNOWN                 WO 2000GB3282  20000824
Priority Applic:                            GB 99206740    19990901

Abstract: The present invention relates to the discovery that various
```

proteins isolated from ticks are effective in the treatment of conjunctivitis . These proteins may most suitably be applied topically to an affected area and are effective to ameliorate the symptoms of this condition.

Exemplary Claim: D R A W I N G

1. Use of a histacalin protein (as defined herein) in the manufacture of a medicament for the treatment or prevention of conjunctivitis .

2/7/2 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2003 Thomson Derwent. All rts. reserv.

013773464
WPI Acc No: 2001-257675/200126
Use of histacalin proteins for treating or preventing non-infective conjunctivitis , or for manufacturing a medicament for treating or preventing conjunctivitis , e.g. seasonal or perennial allergic conjunctivitis
Patent Assignee: EVOLUTEC LTD (EVOL-N); NUTTALL P A (NUTT-I); PAESEN G C (PAES-I)
Inventor: NUTTALL P A; PAESEN G C
Number of Countries: 095 Number of Patents: 005
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 200115719	A2	20010308	WO 2000GB3282	A	20000824	200126	B
AU 200067139	A	20010326	AU 200067139	A	20000824	200137	
BR 200013665	A	20020514	BR 200013665	A	20000824	200240	
			WO 2000GB3282	A	20000824		
EP 1207893	A2	20020529	EP 2000954784	A	20000824	200243	
			WO 2000GB3282	A	20000824		
US 20020151499	A1	20021017	WO 2000GB3282	A	20000824	200270	
			US 200285577	A	20020227		

Priority Applications (No Type Date): GB 9920674 A 19990901
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200115719	A2	E	19	A61K-038/00	
Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
AU 200067139	A			A61K-038/00	Based on patent WO 200115719
BR 200013665	A			A61K-038/00	Based on patent WO 200115719
EP 1207893	A2	E		A61K-038/17	Based on patent WO 200115719
Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
US 20020151499	A1			A61K-038/17	Cont of application WO 2000GB3282

Abstract (Basic): WO 200115719 A2
NOVELTY - Employing a histacalin protein for treating or preventing conjunctivitis , or for manufacturing a medicament for treating or preventing conjunctivitis .
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:
(1) use of a histacalin protein in the manufacture of a medicament for treating or preventing conjunctivitis ;

(2) a pharmaceutical composition comprising a histacalin protein , an antihistamine and a pharmaceutical carrier; and

(3) a method for treating or preventing conjunctivitis comprising administering to a subject a dose of the histacalin protein or the pharmaceutical composition.

ACTIVITY - Anti-inflammatory; antiallergic; antihistamine; opthalmological.

MECHANISM OF ACTION - Histamine inhibitor.

USE - The histacalin protein , pharmaceutical composition or method is useful for treating or preventing conjunctivitis , which is non-infective. Preferably, these are useful for treating or preventing allergic conjunctivitis , e.g. seasonal or perennial allergic conjunctivitis (all claimed). These are also useful in treating or preventing vernal keratoconjunctivitis, giant papillary conjunctivitis or atopic keratoconjunctivitis. The histacalin protein may also be used as a diagnostic tool for evaluating the disease state of a patient suffering from non-infective conjunctivitis . Histacalin protein FS-HBP2 (designated EV131) ophthalmic solution was prepared in 1 % and 6 % concentrations from stock that contained approximately 2 mg EV131 and 50 microl dH2O. Treatment was with either saline, or with 1 % or 6 % EV131 using the rabbit model. Each rabbit was topically dosed in the right eye with 40 microl EV131, and the left eye with 40 microl saline. Five rabbits were dosed with 1 % EV131 and four rabbits were dosed with 6 % EV131. Ten minutes following dosing, 25 microl of 7.5 mg/ml of a solution of Compound 48/80 (a pro-inflammatory compound that promotes the release of allergy mediators, including histamine). A dose of 6 % EV131 was found to give optimum results of consistent reduction in inflammation as measured by hyperemia, chemosis, mucous discharge or lid swelling.

pp; 19 DwgNo 0/6

Derwent Class: B04

International Patent Class (Main): A61K-038/00; A61K-038/17

International Patent Class (Additional): A61P-037/08

2/7/3 (Item 2 from file: 351)

DIALOG(R)File 351:Derwent WPI

013734291

WPI Acc No: 2001-218521/200122

Use of histacalin proteins for treating or preventing allergic rhinitis, or for manufacturing a medicament for treating or preventing allergic rhinitis, e.g. seasonal or perennial allergic rhinitis

Patent Assignee: EVOLUTEC LTD (EVOL-N); NUTTALL P A (NUTT-I); PAESEN G C (PAES-I)

Inventor: NUTTALL P A; PAESEN G C

Number of Countries: 095 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200116164	A2	20010308	WO 2000GB3287	A	20000824	200122 B
AU 200067143	A	20010326	AU 200067143	A	20000824	200137
BR 200013655	A	20020507	BR 200013655	A	20000824	200238
			WO 2000GB3287	A	20000824	
EP 1207899	A2	20020529	EP 2000954788	A	20000824	200243
			WO 2000GB3287	A	20000824	
US 20020193306	A1	20021219	WO 2000GB3287	A	20000824	200303
			US 200287195	A	20020301	
CN 1371471	A	20021002	CN 2000812372	A	20000824	200307

Priority Applications (No Type Date): GB 9920673 A 19990901

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes

WO 200116164 A2 E 19 C07K-014/00
Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
AU 200067143 A C07K-014/00 Based on patent WO 200116164
BR 200013655 A C07K-014/00 Based on patent WO 200116164
EP 1207899 A2 E A61K-038/17 Based on patent WO 200116164
Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
US 20020193306 A1 A61K-038/17 Cont of application WO 2000GB3287
CN 1372471 A A61K-038/17

Abstract (Basic): WO 200116164 A2

NOVELTY - Employing a histacalin protein for treating or preventing allergic rhinitis, or for manufacturing a medicament for treating or preventing allergic rhinitis.

ACTIVITY - Antiinflammatory; antiallergic; opthalmological.

Three subjects were challenged intranasally with histamine at 0.5, 1.0, 2.0, 4.0 or 8 mg/ml concentrations. 45 minutes after the completion of the challenge, baseline measurements were taken. Then a histacalin protein MS-HBP1 (designated EV504) was administered as a fresh solution of pre-weighed aliquots of histacalin in phosphate buffered saline. The solution was administered by dropping from a pipette into each nostril. After a further 15 minutes, a repeat nasal histamine dose-response challenge was administered. The results were recorded as total nasal airway resistance, as measured by active posterior rhinomanometry, and by measurement of anterior nasal secretions. Results showed that anterior nasal secretions and nasal airway resistance was greatly reduced upon administration of the histacalin protein .

MECHANISM OF ACTION - Histamine inhibitor.

USE - The histacalin protein , the medicament or method is useful for treating or preventing allergic rhinitis, both seasonal and perennial allergic conjunctivitis (claimed).

pp; 19 DwgNo 0/8

Derwent Class: B04
International Patent Class (Main): A61K-038/17; C07K-014/00
International Patent Class (Additional): A61P-037/08
?ds

Set	Items	Description
S1	3	HISTACALIN(5W)PROTEIN? AND (ECTOPARASITE? OR TICK?) AND (C-ONJUNCTIVIT? OR EYE? OR OCUL?)
S2	3	RD (unique items)
S3	3600	MS(W)(HBP1 OR HBP(W)1) OR FS(W)(HBP1 OR HBP(W)1) OR FS(W)(-HBP2 OR HBP(W)1) OR D(W)RET6 OR D(W)RET(W)6 OR D(W)RET?
S4	2723	RD (unique items)
S5	49	S4 AND (CONJUNCTIV? OR EYE? OR OCUL?)
S6	2720	S4 NOT S2
S7	28	S6(S)(CONJUNCTIV? OR EYE? OR OCUL?)
S8	6	S3 NOT D(W)RET?
S9	3	S8 NOT S2

?t9/7/1-3

9/7/1 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

10249599 2002-0193306 2002-0050215

C/TREATMENT OF ALLERGIC RHINITIS
Document Type: Utility
Document Type: Patent Application-First Publication **
00001000
Inventors: Nuttall Patricia Anne (GB); Paesen Guido Christiaan (GB)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000

	Kind	Publication Number	Date	Application Number	Date
	A1	US 20020193306	20021219	US 200287195	20020301
Continuation of:		UNKNOWN		WO 2000GB3287	20000824
Priority Applic:				GB 99206732	19990901

Abstract: The invention relates to the discovery that various proteins isolated from ticks are effective in the treatment and prevention of allergic rhinitis. These proteins may most suitably be applied to an effected area and are thus effective to treat this condition and to ameliorate its symptoms.

Exemplary Claim: D R A W I N G

1. Use of a histacalin protein (as defined above) in the manufacture of a medicament for the treatment or prevention of allergic rhinitis.

9/7/2 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI

012551734
WPI Acc No: 1999-357841/199930
Histamine and serotonin binding compounds useful for the treatment of allergies
Patent Assignee: OXFORD VACS LTD (OXFO-N)
Inventor: NUTTALL P A; PAESEN G C
Number of Countries: 084 Number of Patents: 010
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9927104	A1	19990603	WO 98GB3530	A	19981126	199930	B
AU 9912511	A	19990615	AU 9912511	A	19981126	199944	
EP 1034273	A1	20000913	EP 98955786	A	19981126	200046	
			WO 98GB3530	A	19981126		
BR 9815056	A	20001003	BR 9815056	A	19981126	200053	
			WO 98GB3530	A	19981126		
CZ 200001927	A3	20001011	WO 98GB3530	A	19981126	200060	
			CZ 200019?7	A	19981126		
SK 200000791	A3	20001211	WO 98GB3530	A	19981126	200103	
			SK 200079?	A	19981126		
CN 1286726	A	20010307	CN 98813321	A	19981126	200140	
MX 2000005010	A1	20010501	MX 20005010	A	20000522	200227	
JP 2002508927	W	20020326	WO 98GB3530	A	19981126	200236	
			JP 2000522246	A	19981126		
NZ 504753	A	20021122	NZ 504753	A	19981126	200301	
			WO 98GB3530	A	19981126		

Priority Applications (No Type Date): GB 9813917 A 19980626; GB 9725046 A 19971126
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9927104	A1	E	84	C12N-015/21	
Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
AU 9912511	A			C12N-015/21	Based on patent WO 9927104
EP 1034273	A1	E		C12N-015/21	Based on patent WO 9927104
Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT RO SE					
BR 9815056	A			C12N-015/21	Based on patent WO 9927104
CZ 200001927	A3			C12N-015/21	Based on patent WO 9927104
SK 200000791	A3			C12N-015/21	
CN 1286726	A			C12N-015/21	
MX 2000005010	A1			A01K-057/027	
JP 2002503927	W		95	C12N-015/09	Based on patent WO 9927104
NZ 504753	A			C12N-015/21	Based on patent WO 9927104

Abstract (Basic): WO 9927104 A1

NOVELTY - Histamine or serotonin binding compounds (A), are new.

DETAILED DESCRIPTION - (A) has a dissociation constant of less than 10-7 M and a binding site that includes:

(a) Phe, Ile, or Leu at residue I, Trp at residue II, and Asp or Glu at II and IV where residues I-IV are positioned as in residues 103, 43, 39, and 82 of sequences (I) (190 aa, given in the specification) or (II) (190 aa, given in the specification), residues 107, 41, 38, and 78 of sequence (III) (200 aa given in the specification), or residues 122, 54, 50, and 95 of sequence (IV) (209 aa given in the specification).

INDEPENDENT CLAIMS are also included for the following:

(1) compounds as above with Phe or Ile at residue I, Trp at residue II, and Asp or Glu at residue III or IV of the binding site where residues I-IV are positioned according to residues 98, 137, 24, and 120 of sequences (I) or (II), residues 95, 138, 23, and 129 of sequence (III), or residues 112, 149, 35, and 135 of sequence (IV);

(2) a histamine binding compound capable of binding histamine or serotonin that has 2 binding sites, 1 as in (a), the other as in (1);

(3) a protein comprising Ra-Res of amino acid sequence (V) (207 aa, given in the specification), or an equivalent derivative or fragment;

(4) a protein comprising Av-HBP of amino acid sequence (VI) (178 aa, given in the specification), or an equivalent derivative or fragment;

(5) a protein comprising Ih/Bm-HBP1 of amino acid sequence (VII) (203 aa, given in the specification), or an equivalent derivative or fragment;

(6) a protein comprising Ih/Bm-HBP2 of amino acid sequence (VIII) (203 aa, given in the specification), or an equivalent derivative or fragment;

(7) a protein comprising Ih/Bm-HBP3 of amino acid sequence (IX) (285 aa, given in the specification), or an equivalent derivative or fragment;

(8) a protein comprising Ih/Bm-HBP4 of amino acid sequence (X) (284 aa, given in the specification), or an equivalent derivative or fragment;

(9) a protein comprising Ih/Bm-HBP5 of amino acid sequence (XI) (321 aa, given in the specification), or an equivalent derivative or fragment.

(10) a nucleic acid encoding a compound of claims (a) and (1)-(9);

(11) a vector containing the nucleic acid molecule of (10);

(12) a host cell transformed with the vector of (11); and

(13) a transgenic animal transformed by the nucleic acid of (11) or

the vector of (12).

ACTIVITY - Anti-inflammatory; antihistamine; antiallergic; anti-asthmatic; cytostatic; antimigrane; dermatological;

MECHANISM OF ACTION - Histamine and serotonin binding.

USE - The compounds are useful for regulating the action of histamine and serotonin (in e.g. inflammation and gastric acid secretion), the detection, quantification and removal of histamine or serotonin (in animals, plants, cell cultures, food materials, or humans) and in the treatment of various diseases and allergies (e.g. type I hypersensitivity reactions, urticaria, asthma, allergic rhinitis (hay fever), atopic dermatitis, insect bites and food and drug allergies, abnormal blood pressure, migraine, psychological disorders, respiratory disease, and coronary heart disease). Histamine may also be used to regulate cellular growth and tissue repair. The molecules may also be used as components of vaccines directed against blood-sucking ectoparasites.

pp; 84 DwgNo 0/22

Derwent Class: B04; C03; C06; D13; D16; P14; S03

International Patent Class (Main): A01K-057/027; C12N-015/09; C12N-015/21

International Patent Class (Additional): A01K-067/027; A23L-001/015; A23L-001/05; A61P-031/19; A61K-031/35; A61K-031/40; A61K-031/66; A61K-038/00; A61P-038/17; A61K-045/00; A61K-048/00; A61P-037/00; A61P-043/00; C07K-014/435; C07K-017/00; C12N-001/21; C12N-005/10; C12N-015/00; G01N-033/68

9/7/3 (Item 2 from file: 351)

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

011601378

WPI Acc No: 1998-018506/199802

New vasoactive amine binding proteins and related nucleic acid, vectors - transformed cells and transgenic animals, used for assaying or removing histamine and as antihistamine or anti-inflammatory agents

Patent Assignee: OXFORD VACS LTD (OXFO-N)

Inventor: NUTTALL P A; PAESEN G C

Number of Countries: 077 Number of Patents: 009

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9744451	A2	19971127	WO 97GB1372	A	19970519	199802	B
AU 9729071	A	19971209	AU 9729071	A	19970519	199824	
EP 906425	A2	19990407	EP 97923204	A	19970519	199918	
			WO 97GB1372	A	19970519		
CN 1225683	A	19990811	CN 97196317	A	19970519	199950	
BR 9709101	A	19990803	BR 979101	A	19970519	199952	
			WO 97GB1372	A	19970519		
NZ 332648	A	20000526	NZ 332648	A	19970519	200033	
			WO 97GB1372	A	19970519		
JP 2000512489	W	20000926	JP 97541799	A	19970519	200051	
			WO 97GB1372	A	19970519		
MX 9809509	A1	19990301	MX 989509	A	19981113	200051	
AU 725630	B	20001019	AU 9729071	A	19970519	200057	

Priority Applications (No Type Date): GB 977844 A 19970418; GB 9610484 A 19960518

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9744451	A2	E	44	C12N-015/12	

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG

US UZ VN YU
Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

AU	9729071	A		C12N-015/12	Based on patent WO 9744451
EP	906425	A2 E		C12N-015/12	Based on patent WO 9744451
	Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT RO SE				
CN	1225683	A		C12N-015/12	
BR	9709101	A		C12N-015/12	Based on patent WO 9744451
NZ	332648	A		C12Q-001/68	Based on patent WO 9744451
JP	2000512489	W	44	C12N-015/09	Based on patent WO 9744451
MX	9809509	A1		C12N-015/12	
AU	725630	B		C12N-015/12	Previous Publ. patent AU 9729071 Based on patent WO 9744451

Abstract (Basic): WO 9744451 A

Vasoactive amine binding proteins (VABP) that bind specifically to vasoactive amines (VA) with dissociation constant below 0.1 mu M and belong to the same protein family as MS - HBP1 ; FS - HBP1 or 2, or D . RET6 are new. Also new are (1) functional fragments and derivatives of VABP; (2) nucleic acid (I) encoding VABP or hybridising with the coding sequence; (3) cloning or expression vectors containing (I); (4) host cells transformed or transfected with these vectors; (5) transgenic animals containing (I).

USE - The host cells are used to produce recombinant VABP. VABP are used (i) to detect or quantify histamine (or other VA such as serotonin) in body fluids or cell culture supernatants, e.g. to monitor the effect of allergens; (ii) for binding VA, e.g. to remove histamine from blood, food, cell cultures etc.; (iii) as an antihistamine or anti-inflammatory agent, e.g. for treating insect, snake or scorpion bites or dermatitis, or as a carrier for slow release of histamine-related compounds; (iv) in vaccines to protect against metazoan parasites, especially in animals; (v) as reagents for studying inflammation, involvement of VA in ulcer formation or the immune response etc.

ADVANTAGE - VABP provide a more sensitive assay for histamine than low-affinity antibodies currently used. They may also be more effective and safer than conventional antihistamines.

Dwg.0/10

Derwent Class: B04; D16; P14; S03
International Patent Class (Main): C12N-015/09; C12N-015/12; C12Q-001/68
International Patent Class (Additional): A01K-067/027; A61K-035/56; A61K-035/58; A61K-035/64; A61K-038/17; A61K-039/38; C07K-014/435; C07K-017/00; C07K-019/00; C12N-005/10; C12N-015/62; C12N-015/86; C12P-021/02; G01N-033/68
?